JP2019515661A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019515661A5 JP2019515661A5 JP2018550679A JP2018550679A JP2019515661A5 JP 2019515661 A5 JP2019515661 A5 JP 2019515661A5 JP 2018550679 A JP2018550679 A JP 2018550679A JP 2018550679 A JP2018550679 A JP 2018550679A JP 2019515661 A5 JP2019515661 A5 JP 2019515661A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- cell
- amino acid
- acid sequence
- polynucleotide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004027 cell Anatomy 0.000 claims description 26
- 108020004414 DNA Proteins 0.000 claims description 21
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 21
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 11
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 claims description 10
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 claims description 10
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 7
- 206010028980 Neoplasm Diseases 0.000 claims description 6
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 4
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 4
- 208000034578 Multiple myelomas Diseases 0.000 claims description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 3
- 201000011510 cancer Diseases 0.000 claims description 3
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims description 2
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims description 2
- 241000713666 Lentivirus Species 0.000 claims description 2
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims description 2
- 108091033319 polynucleotide Proteins 0.000 claims 26
- 239000002157 polynucleotide Substances 0.000 claims 26
- 102000040430 polynucleotide Human genes 0.000 claims 26
- 125000003275 alpha amino acid group Chemical group 0.000 claims 21
- 108091008874 T cell receptors Proteins 0.000 claims 9
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 9
- 239000002773 nucleotide Substances 0.000 claims 9
- 125000003729 nucleotide group Chemical group 0.000 claims 9
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 7
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims 7
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 7
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims 7
- 230000000139 costimulatory effect Effects 0.000 claims 7
- 239000000427 antigen Substances 0.000 claims 6
- 102000036639 antigens Human genes 0.000 claims 6
- 108091007433 antigens Proteins 0.000 claims 6
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 4
- -1 CD8alpha Proteins 0.000 claims 4
- 208000007452 Plasmacytoma Diseases 0.000 claims 4
- 102100029215 Signaling lymphocytic activation molecule Human genes 0.000 claims 4
- 201000003444 follicular lymphoma Diseases 0.000 claims 4
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 3
- 102100038078 CD276 antigen Human genes 0.000 claims 3
- 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 claims 3
- 101000633786 Homo sapiens SLAM family member 6 Proteins 0.000 claims 3
- 102100032816 Integrin alpha-6 Human genes 0.000 claims 3
- 102100022339 Integrin alpha-L Human genes 0.000 claims 3
- 102100025390 Integrin beta-2 Human genes 0.000 claims 3
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 3
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 claims 3
- 206010053869 POEMS syndrome Diseases 0.000 claims 3
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 3
- 102100029197 SLAM family member 6 Human genes 0.000 claims 3
- 108010074687 Signaling Lymphocytic Activation Molecule Family Member 1 Proteins 0.000 claims 3
- 230000004913 activation Effects 0.000 claims 3
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 3
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 2
- 102100024263 CD160 antigen Human genes 0.000 claims 2
- 102100038077 CD226 antigen Human genes 0.000 claims 2
- 101710185679 CD276 antigen Proteins 0.000 claims 2
- 101000761938 Homo sapiens CD160 antigen Proteins 0.000 claims 2
- 101000884298 Homo sapiens CD226 antigen Proteins 0.000 claims 2
- 101001078158 Homo sapiens Integrin alpha-1 Proteins 0.000 claims 2
- 101000994375 Homo sapiens Integrin alpha-4 Proteins 0.000 claims 2
- 101000994365 Homo sapiens Integrin alpha-6 Proteins 0.000 claims 2
- 101001035237 Homo sapiens Integrin alpha-D Proteins 0.000 claims 2
- 101001046687 Homo sapiens Integrin alpha-E Proteins 0.000 claims 2
- 101000935043 Homo sapiens Integrin beta-1 Proteins 0.000 claims 2
- 101000971538 Homo sapiens Killer cell lectin-like receptor subfamily F member 1 Proteins 0.000 claims 2
- 101000633780 Homo sapiens Signaling lymphocytic activation molecule Proteins 0.000 claims 2
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 claims 2
- 102100025323 Integrin alpha-1 Human genes 0.000 claims 2
- 102100032818 Integrin alpha-4 Human genes 0.000 claims 2
- 102100039904 Integrin alpha-D Human genes 0.000 claims 2
- 102100022341 Integrin alpha-E Human genes 0.000 claims 2
- 102100022338 Integrin alpha-M Human genes 0.000 claims 2
- 102100022297 Integrin alpha-X Human genes 0.000 claims 2
- 102100025304 Integrin beta-1 Human genes 0.000 claims 2
- 102100021458 Killer cell lectin-like receptor subfamily F member 1 Human genes 0.000 claims 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 2
- 102100038082 Natural killer cell receptor 2B4 Human genes 0.000 claims 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 2
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 2
- 102100027744 Semaphorin-4D Human genes 0.000 claims 2
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 claims 2
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 claims 2
- 102000006707 alpha-beta T-Cell Antigen Receptors Human genes 0.000 claims 2
- 108010087408 alpha-beta T-Cell Antigen Receptors Proteins 0.000 claims 2
- 238000003782 apoptosis assay Methods 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 239000003446 ligand Substances 0.000 claims 2
- 230000005522 programmed cell death Effects 0.000 claims 2
- 208000010721 smoldering plasma cell myeloma Diseases 0.000 claims 2
- 206010062113 splenic marginal zone lymphoma Diseases 0.000 claims 2
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 claims 2
- 241000701161 unidentified adenovirus Species 0.000 claims 2
- ZUXNHFFVQWADJL-UHFFFAOYSA-N 3,4,5-trimethoxy-n-(2-methoxyethyl)-n-(4-phenyl-1,3-thiazol-2-yl)benzamide Chemical compound N=1C(C=2C=CC=CC=2)=CSC=1N(CCOC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 ZUXNHFFVQWADJL-UHFFFAOYSA-N 0.000 claims 1
- 208000023761 AL amyloidosis Diseases 0.000 claims 1
- 206010000830 Acute leukaemia Diseases 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 claims 1
- 208000036170 B-Cell Marginal Zone Lymphoma Diseases 0.000 claims 1
- 208000025324 B-cell acute lymphoblastic leukemia Diseases 0.000 claims 1
- 102100027205 B-cell antigen receptor complex-associated protein alpha chain Human genes 0.000 claims 1
- 101710095183 B-cell antigen receptor complex-associated protein alpha chain Proteins 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000032568 B-cell prolymphocytic leukaemia Diseases 0.000 claims 1
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims 1
- 208000011691 Burkitt lymphomas Diseases 0.000 claims 1
- 108010056102 CD100 antigen Proteins 0.000 claims 1
- 108010017009 CD11b Antigen Proteins 0.000 claims 1
- 102100027207 CD27 antigen Human genes 0.000 claims 1
- 208000016778 CD4+/CD56+ hematodermic neoplasm Diseases 0.000 claims 1
- 101150013553 CD40 gene Proteins 0.000 claims 1
- 102100032937 CD40 ligand Human genes 0.000 claims 1
- 108010062802 CD66 antigens Proteins 0.000 claims 1
- 102100027217 CD82 antigen Human genes 0.000 claims 1
- 101710139831 CD82 antigen Proteins 0.000 claims 1
- 102100035793 CD83 antigen Human genes 0.000 claims 1
- 102100037904 CD9 antigen Human genes 0.000 claims 1
- 102100024533 Carcinoembryonic antigen-related cell adhesion molecule 1 Human genes 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- 102100025137 Early activation antigen CD69 Human genes 0.000 claims 1
- 101000585551 Equus caballus Pregnancy-associated glycoprotein Proteins 0.000 claims 1
- 206010061850 Extranodal marginal zone B-cell lymphoma (MALT type) Diseases 0.000 claims 1
- 102100022086 GRB2-related adapter protein 2 Human genes 0.000 claims 1
- 102100028976 HLA class I histocompatibility antigen, B alpha chain Human genes 0.000 claims 1
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 claims 1
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 claims 1
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims 1
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims 1
- 101000868215 Homo sapiens CD40 ligand Proteins 0.000 claims 1
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 claims 1
- 101000738354 Homo sapiens CD9 antigen Proteins 0.000 claims 1
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 claims 1
- 101000900690 Homo sapiens GRB2-related adapter protein 2 Proteins 0.000 claims 1
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 claims 1
- 101001046683 Homo sapiens Integrin alpha-L Proteins 0.000 claims 1
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 claims 1
- 101001046668 Homo sapiens Integrin alpha-X Proteins 0.000 claims 1
- 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 claims 1
- 101001047640 Homo sapiens Linker for activation of T-cells family member 1 Proteins 0.000 claims 1
- 101001090688 Homo sapiens Lymphocyte cytosolic protein 2 Proteins 0.000 claims 1
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims 1
- 101001109503 Homo sapiens NKG2-C type II integral membrane protein Proteins 0.000 claims 1
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 claims 1
- 101000589305 Homo sapiens Natural cytotoxicity triggering receptor 2 Proteins 0.000 claims 1
- 101000873418 Homo sapiens P-selectin glycoprotein ligand 1 Proteins 0.000 claims 1
- 101001124867 Homo sapiens Peroxiredoxin-1 Proteins 0.000 claims 1
- 101000692259 Homo sapiens Phosphoprotein associated with glycosphingolipid-enriched microdomains 1 Proteins 0.000 claims 1
- 101000702132 Homo sapiens Protein spinster homolog 1 Proteins 0.000 claims 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims 1
- 101000633778 Homo sapiens SLAM family member 5 Proteins 0.000 claims 1
- 101000633784 Homo sapiens SLAM family member 7 Proteins 0.000 claims 1
- 101000914496 Homo sapiens T-cell antigen CD7 Proteins 0.000 claims 1
- 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 claims 1
- 101000934341 Homo sapiens T-cell surface glycoprotein CD5 Proteins 0.000 claims 1
- 101000596234 Homo sapiens T-cell surface protein tactile Proteins 0.000 claims 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims 1
- 101000795169 Homo sapiens Tumor necrosis factor receptor superfamily member 13C Proteins 0.000 claims 1
- 101000648507 Homo sapiens Tumor necrosis factor receptor superfamily member 14 Proteins 0.000 claims 1
- 101000679857 Homo sapiens Tumor necrosis factor receptor superfamily member 3 Proteins 0.000 claims 1
- 101000679851 Homo sapiens Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 1
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims 1
- 102000009490 IgG Receptors Human genes 0.000 claims 1
- 108010073807 IgG Receptors Proteins 0.000 claims 1
- 108010041100 Integrin alpha6 Proteins 0.000 claims 1
- 108010030465 Integrin alpha6beta1 Proteins 0.000 claims 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 claims 1
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 claims 1
- 102100031586 Leukocyte antigen CD37 Human genes 0.000 claims 1
- 102100024032 Linker for activation of T-cells family member 1 Human genes 0.000 claims 1
- 102100034709 Lymphocyte cytosolic protein 2 Human genes 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 201000003791 MALT lymphoma Diseases 0.000 claims 1
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims 1
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims 1
- 108091008877 NK cell receptors Proteins 0.000 claims 1
- 102100022683 NKG2-C type II integral membrane protein Human genes 0.000 claims 1
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 claims 1
- 108010004217 Natural Cytotoxicity Triggering Receptor 1 Proteins 0.000 claims 1
- 108010004222 Natural Cytotoxicity Triggering Receptor 3 Proteins 0.000 claims 1
- 102100032870 Natural cytotoxicity triggering receptor 1 Human genes 0.000 claims 1
- 102100032851 Natural cytotoxicity triggering receptor 2 Human genes 0.000 claims 1
- 102100032852 Natural cytotoxicity triggering receptor 3 Human genes 0.000 claims 1
- 101710141230 Natural killer cell receptor 2B4 Proteins 0.000 claims 1
- 102100021462 Natural killer cells antigen CD94 Human genes 0.000 claims 1
- 102100034925 P-selectin glycoprotein ligand 1 Human genes 0.000 claims 1
- 102100026066 Phosphoprotein associated with glycosphingolipid-enriched microdomains 1 Human genes 0.000 claims 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims 1
- 208000009052 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 206010036711 Primary mediastinal large B-cell lymphomas Diseases 0.000 claims 1
- 208000035416 Prolymphocytic B-Cell Leukemia Diseases 0.000 claims 1
- 102000014128 RANK Ligand Human genes 0.000 claims 1
- 108010025832 RANK Ligand Proteins 0.000 claims 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims 1
- 102100029216 SLAM family member 5 Human genes 0.000 claims 1
- 102100029198 SLAM family member 7 Human genes 0.000 claims 1
- 102000008115 Signaling Lymphocytic Activation Molecule Family Member 1 Human genes 0.000 claims 1
- 208000004346 Smoldering Multiple Myeloma Diseases 0.000 claims 1
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 claims 1
- 102100027208 T-cell antigen CD7 Human genes 0.000 claims 1
- 206010042971 T-cell lymphoma Diseases 0.000 claims 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims 1
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 claims 1
- 102100025244 T-cell surface glycoprotein CD5 Human genes 0.000 claims 1
- 102100035268 T-cell surface protein tactile Human genes 0.000 claims 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims 1
- 108010065158 Tumor Necrosis Factor Ligand Superfamily Member 14 Proteins 0.000 claims 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 claims 1
- 102100024586 Tumor necrosis factor ligand superfamily member 14 Human genes 0.000 claims 1
- 102100029690 Tumor necrosis factor receptor superfamily member 13C Human genes 0.000 claims 1
- 102100033733 Tumor necrosis factor receptor superfamily member 1B Human genes 0.000 claims 1
- 101710187830 Tumor necrosis factor receptor superfamily member 1B Proteins 0.000 claims 1
- 102100022156 Tumor necrosis factor receptor superfamily member 3 Human genes 0.000 claims 1
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims 1
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims 1
- 101001038499 Yarrowia lipolytica (strain CLIB 122 / E 150) Lysine acetyltransferase Proteins 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 230000000735 allogeneic effect Effects 0.000 claims 1
- 208000035269 cancer or benign tumor Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000024207 chronic leukemia Diseases 0.000 claims 1
- 102000003675 cytokine receptors Human genes 0.000 claims 1
- 108010057085 cytokine receptors Proteins 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 201000006569 extramedullary plasmacytoma Diseases 0.000 claims 1
- 230000003325 follicular Effects 0.000 claims 1
- 108010074605 gamma-Globulins Proteins 0.000 claims 1
- 201000009277 hairy cell leukemia Diseases 0.000 claims 1
- 230000036039 immunity Effects 0.000 claims 1
- 208000015266 indolent plasma cell myeloma Diseases 0.000 claims 1
- 102000006495 integrins Human genes 0.000 claims 1
- 108010044426 integrins Proteins 0.000 claims 1
- 210000004698 lymphocyte Anatomy 0.000 claims 1
- 230000001589 lymphoproliferative effect Effects 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 201000007924 marginal zone B-cell lymphoma Diseases 0.000 claims 1
- 208000021937 marginal zone lymphoma Diseases 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 229910052698 phosphorus Inorganic materials 0.000 claims 1
- 239000011574 phosphorus Substances 0.000 claims 1
- 208000007525 plasmablastic lymphoma Diseases 0.000 claims 1
- 210000005134 plasmacytoid dendritic cell Anatomy 0.000 claims 1
- 239000013612 plasmid Substances 0.000 claims 1
- 210000004180 plasmocyte Anatomy 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 230000019491 signal transduction Effects 0.000 claims 1
- 230000011664 signaling Effects 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 102000003390 tumor necrosis factor Human genes 0.000 claims 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 claims 1
- 241001430294 unidentified retrovirus Species 0.000 claims 1
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 description 24
- 108091007741 Chimeric antigen receptor T cells Proteins 0.000 description 10
- 230000014509 gene expression Effects 0.000 description 9
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 description 6
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 4
- 230000001461 cytolytic effect Effects 0.000 description 4
- 101710178046 Chorismate synthase 1 Proteins 0.000 description 3
- 101710152695 Cysteine synthase 1 Proteins 0.000 description 3
- 102100032831 Protein ITPRID2 Human genes 0.000 description 3
- 239000012636 effector Substances 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000002864 sequence alignment Methods 0.000 description 3
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 2
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 2
- 101000874179 Homo sapiens Syndecan-1 Proteins 0.000 description 2
- 102100035721 Syndecan-1 Human genes 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 210000001806 memory b lymphocyte Anatomy 0.000 description 2
- 102100026094 C-type lectin domain family 12 member A Human genes 0.000 description 1
- 101710188619 C-type lectin domain family 12 member A Proteins 0.000 description 1
- 102100025221 CD70 antigen Human genes 0.000 description 1
- 102100036466 Delta-like protein 3 Human genes 0.000 description 1
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 description 1
- 101000928513 Homo sapiens Delta-like protein 3 Proteins 0.000 description 1
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 1
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 description 1
- 210000002203 alpha-beta t lymphocyte Anatomy 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 210000001878 cd38-negative naive b cell Anatomy 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 229940127276 delta-like ligand 3 Drugs 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004073 interleukin-2 production Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 238000002887 multiple sequence alignment Methods 0.000 description 1
- 210000000066 myeloid cell Anatomy 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
Images
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022019896A JP2022065073A (ja) | 2016-04-01 | 2022-02-10 | Ｂｃｍａ結合分子及びその使用方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662317334P | 2016-04-01 | 2016-04-01 | |
| US62/317,334 | 2016-04-01 | ||
| PCT/US2017/025516 WO2017173349A1 (en) | 2016-04-01 | 2017-03-31 | Bcma binding molecules and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022019896A Division JP2022065073A (ja) | 2016-04-01 | 2022-02-10 | Ｂｃｍａ結合分子及びその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019515661A JP2019515661A (ja) | 2019-06-13 |
| JP2019515661A5 true JP2019515661A5 (enExample) | 2020-05-07 |
| JP7366543B2 JP7366543B2 (ja) | 2023-10-23 |
Family
ID=59959188
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018550679A Active JP7366543B2 (ja) | 2016-04-01 | 2017-03-31 | Ｂｃｍａ結合分子及びその使用方法 |
| JP2022019896A Pending JP2022065073A (ja) | 2016-04-01 | 2022-02-10 | Ｂｃｍａ結合分子及びその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022019896A Pending JP2022065073A (ja) | 2016-04-01 | 2022-02-10 | Ｂｃｍａ結合分子及びその使用方法 |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US10689450B2 (enExample) |
| EP (1) | EP3436036A4 (enExample) |
| JP (2) | JP7366543B2 (enExample) |
| KR (3) | KR102397674B1 (enExample) |
| CN (3) | CN109414455B (enExample) |
| AR (1) | AR108067A1 (enExample) |
| AU (2) | AU2017240150C1 (enExample) |
| BR (1) | BR112018070159A2 (enExample) |
| CA (1) | CA3019135A1 (enExample) |
| CL (1) | CL2018002763A1 (enExample) |
| CO (1) | CO2018010475A2 (enExample) |
| CR (1) | CR20180462A (enExample) |
| CU (1) | CU20180120A7 (enExample) |
| DO (1) | DOP2018000212A (enExample) |
| EA (1) | EA201891966A1 (enExample) |
| EC (1) | ECSP18073836A (enExample) |
| IL (1) | IL261942A (enExample) |
| MX (1) | MX2023007400A (enExample) |
| NZ (1) | NZ746700A (enExample) |
| PE (1) | PE20190120A1 (enExample) |
| PH (1) | PH12018550164A1 (enExample) |
| SG (2) | SG11201808403SA (enExample) |
| TW (4) | TWI795133B (enExample) |
| WO (1) | WO2017173349A1 (enExample) |
| ZA (1) | ZA201806962B (enExample) |
Families Citing this family (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HK1259075A1 (zh) | 2016-02-17 | 2019-11-22 | Seattle Genetics, Inc. | Bcma抗体和其用以治疗癌症和免疫病症的用途 |
| PL3436079T3 (pl) | 2016-04-01 | 2021-12-20 | Kite Pharma, Inc. | Antygen chimeryczny i receptory komórek t oraz sposoby ich stosowania |
| SG11201808403SA (en) | 2016-04-01 | 2018-10-30 | Kite Pharma Inc | Bcma binding molecules and methods of use thereof |
| PT3436030T (pt) | 2016-04-01 | 2022-11-18 | Amgen Inc | Recetores quiméricos e métodos para a sua utilização |
| US12269859B2 (en) | 2016-12-02 | 2025-04-08 | Angeles Therapeutics, Inc. | Synthetic immune receptors and methods of use thereof |
| US20200016207A1 (en) * | 2017-03-20 | 2020-01-16 | Baylor College Of Medicine | TRANSGENIC c-MPL PROVIDES LIGAND-DEPENDENT CO-STIMULATION AND CYTOKINE SIGNALS TO TCR-ENGINEERED T CELLS |
| WO2018209324A2 (en) | 2017-05-11 | 2018-11-15 | The Broad Institute, Inc. | Methods and compositions of use of cd8+ tumor infiltrating lymphocyte subtypes and gene signatures thereof |
| WO2018232195A1 (en) | 2017-06-14 | 2018-12-20 | The Broad Institute, Inc. | Compositions and methods targeting complement component 3 for inhibiting tumor growth |
| US12049643B2 (en) | 2017-07-14 | 2024-07-30 | The Broad Institute, Inc. | Methods and compositions for modulating cytotoxic lymphocyte activity |
| AU2018326805B2 (en) | 2017-09-01 | 2023-11-30 | Dana-Farber Cancer Institute, Inc. | Immunogenic peptides specific to BCMA and TACI antigens for treatment of cancer |
| EP3695408A4 (en) | 2017-10-02 | 2021-12-15 | The Broad Institute, Inc. | METHODS AND COMPOSITIONS FOR DETECTING AND MODULATING A GENETIC SIGNATURE OF IMMUNOTHERAPY RESISTANCE IN CANCER |
| WO2019089982A1 (en) | 2017-11-01 | 2019-05-09 | Juno Therapeutics, Inc. | Method of assessing activity of recombinant antigen receptors |
| PL3703750T3 (pl) | 2017-11-01 | 2025-04-07 | Juno Therapeutics, Inc. | Chimeryczne receptory antygenowe specyficzne dla antygenu dojrzewania komórek b i kodujące polinukleotydy |
| CA3080395A1 (en) | 2017-11-06 | 2019-05-09 | Juno Therapeutics, Inc. | Combination of a cell therapy and a gamma secretase inhibitor |
| US12171783B2 (en) | 2017-11-13 | 2024-12-24 | The Broad Institute, Inc. | Methods and compositions for targeting developmental and oncogenic programs in H3K27M gliomas |
| EP3710039A4 (en) | 2017-11-13 | 2021-08-04 | The Broad Institute, Inc. | METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER BY TARGETING THE CLEC2D-KLRB1 PATH |
| EP3710471A1 (en) | 2017-11-16 | 2020-09-23 | Kite Pharma, Inc. | Modified chimeric antigen receptors and methods of use |
| WO2019154313A1 (zh) | 2018-02-11 | 2019-08-15 | 江苏恒瑞医药股份有限公司 | 一种分离的嵌合抗原受体以及包含其的修饰t细胞及用途 |
| EP3752531A1 (en) * | 2018-02-14 | 2020-12-23 | Kite Pharma, Inc. | Anti-idiotypic antibodies directed to the antigen-binding portion of an bcma-binding molecule |
| BR112020017053A2 (pt) * | 2018-02-21 | 2020-12-15 | Celgene Corporation | Anticorpos que se ligam ao bcma e usos dos mesmos |
| US11957695B2 (en) | 2018-04-26 | 2024-04-16 | The Broad Institute, Inc. | Methods and compositions targeting glucocorticoid signaling for modulating immune responses |
| EP3784272A1 (en) * | 2018-04-27 | 2021-03-03 | CRISPR Therapeutics AG | Anti-bcma car-t-cells for plasma cell depletion |
| WO2019232542A2 (en) | 2018-06-01 | 2019-12-05 | Massachusetts Institute Of Technology | Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients |
| US12036240B2 (en) | 2018-06-14 | 2024-07-16 | The Broad Institute, Inc. | Compositions and methods targeting complement component 3 for inhibiting tumor growth |
| PT3823665T (pt) | 2018-07-19 | 2024-02-26 | Regeneron Pharma | Recetores antigénicos quiméricos que possuem uma especificidade para o bcma e utilizações dos mesmos |
| TWI838389B (zh) | 2018-07-19 | 2024-04-11 | 美商再生元醫藥公司 | 雙特異性抗-BCMAｘ抗-CD3抗體及其用途 |
| CN110818802B (zh) * | 2018-08-08 | 2022-02-08 | 华夏英泰（北京）生物技术有限公司 | 一种嵌合t细胞受体star及其应用 |
| US20230132385A9 (en) * | 2018-09-20 | 2023-04-27 | Tikcro Technologies Ltd. | Antibodies specific to ctla-4 and uses thereof |
| ES3012752T3 (en) | 2018-09-27 | 2025-04-10 | Autolus Ltd | Chimeric antigen receptor |
| WO2020072700A1 (en) | 2018-10-02 | 2020-04-09 | Dana-Farber Cancer Institute, Inc. | Hla single allele lines |
| WO2020081730A2 (en) | 2018-10-16 | 2020-04-23 | Massachusetts Institute Of Technology | Methods and compositions for modulating microenvironment |
| US20220170097A1 (en) | 2018-10-29 | 2022-06-02 | The Broad Institute, Inc. | Car t cell transcriptional atlas |
| CA3117419A1 (en) | 2018-11-01 | 2020-05-07 | Juno Therapeutics, Inc. | Methods for treatment using chimeric antigen receptors specific for b-cell maturation antigen |
| WO2020131586A2 (en) | 2018-12-17 | 2020-06-25 | The Broad Institute, Inc. | Methods for identifying neoantigens |
| EP3670530A1 (en) * | 2018-12-18 | 2020-06-24 | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft | Cd22-specific t cell receptors and adoptive t cell therapy for treatment of b cell malignancies |
| US11739156B2 (en) | 2019-01-06 | 2023-08-29 | The Broad Institute, Inc. Massachusetts Institute of Technology | Methods and compositions for overcoming immunosuppression |
| CA3131138A1 (en) * | 2019-03-06 | 2020-09-10 | Dana-Farber Cancer Institute, Inc. | T cell receptors specific to b-cell maturation antigen for treatment of cancer |
| US20220154282A1 (en) | 2019-03-12 | 2022-05-19 | The Broad Institute, Inc. | Detection means, compositions and methods for modulating synovial sarcoma cells |
| EP3942023A1 (en) | 2019-03-18 | 2022-01-26 | The Broad Institute, Inc. | Compositions and methods for modulating metabolic regulators of t cell pathogenicity |
| US20220235340A1 (en) | 2019-05-20 | 2022-07-28 | The Broad Institute, Inc. | Novel crispr-cas systems and uses thereof |
| KR20220038362A (ko) | 2019-07-02 | 2022-03-28 | 프레드 헛친슨 켄서 리서치 센터 | 재조합 ad35 벡터 및 관련 유전자 요법 개선 |
| WO2021030627A1 (en) | 2019-08-13 | 2021-02-18 | The General Hospital Corporation | Methods for predicting outcomes of checkpoint inhibition and treatment thereof |
| US12421557B2 (en) | 2019-08-16 | 2025-09-23 | The Broad Institute, Inc. | Methods for predicting outcomes and treating colorectal cancer using a cell atlas |
| US20220298501A1 (en) | 2019-08-30 | 2022-09-22 | The Broad Institute, Inc. | Crispr-associated mu transposase systems |
| US12297426B2 (en) | 2019-10-01 | 2025-05-13 | The Broad Institute, Inc. | DNA damage response signature guided rational design of CRISPR-based systems and therapies |
| US12394502B2 (en) | 2019-10-02 | 2025-08-19 | The General Hospital Corporation | Method for predicting HLA-binding peptides using protein structural features |
| US11981922B2 (en) | 2019-10-03 | 2024-05-14 | Dana-Farber Cancer Institute, Inc. | Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment |
| US12195725B2 (en) | 2019-10-03 | 2025-01-14 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for modulating and detecting tissue specific TH17 cell pathogenicity |
| US11793787B2 (en) | 2019-10-07 | 2023-10-24 | The Broad Institute, Inc. | Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis |
| US11844800B2 (en) | 2019-10-30 | 2023-12-19 | Massachusetts Institute Of Technology | Methods and compositions for predicting and preventing relapse of acute lymphoblastic leukemia |
| CN113045657B (zh) * | 2019-12-26 | 2022-06-07 | 杭州济元基因科技有限公司 | 一种人源化抗人bcma单克隆抗体及其car-t细胞 |
| US12165747B2 (en) | 2020-01-23 | 2024-12-10 | The Broad Institute, Inc. | Molecular spatial mapping of metastatic tumor microenvironment |
| CN111234020B (zh) * | 2020-01-23 | 2020-10-23 | 和铂医药(苏州)有限公司 | 一种bcma结合蛋白及其制备方法和应用 |
| WO2021231959A1 (en) * | 2020-05-15 | 2021-11-18 | Precision Biosciences, Inc. | Methods for immunotherapy |
| WO2022156739A1 (zh) * | 2021-01-20 | 2022-07-28 | 江苏恒瑞医药股份有限公司 | 特异性结合bcma和cd3的抗原结合分子及其医药用途 |
| GB202100754D0 (en) | 2021-01-20 | 2021-03-03 | Coding Bio Ltd | Methods for high throughput screening of chimeric antigen receptors |
| CA3208273A1 (en) | 2021-01-20 | 2022-07-28 | Coding Bio Limited | Methods for high throughput screening of chimeric antigen receptors |
| WO2023019398A1 (en) * | 2021-08-16 | 2023-02-23 | Utc Therapeutics (Shanghai) Co., Ltd. | Bcma targetting antibodies, chimeric antigen receptors, and uses thereof |
| GB202116514D0 (en) | 2021-11-16 | 2021-12-29 | Coding Bio Ltd | Computational methods for the design and optimisation of chimeric antigen receptors (cars) |
| WO2023167903A2 (en) * | 2022-03-01 | 2023-09-07 | Agilent Technologies, Inc. | Anti-human b cell maturation antigen (bcma) antibodies and their use in immunohistochemistry (ihc) |
| WO2024077256A1 (en) | 2022-10-07 | 2024-04-11 | The General Hospital Corporation | Methods and compositions for high-throughput discovery ofpeptide-mhc targeting binding proteins |
| WO2024124044A1 (en) | 2022-12-07 | 2024-06-13 | The Brigham And Women’S Hospital, Inc. | Compositions and methods targeting sat1 for enhancing anti¬ tumor immunity during tumor progression |
| WO2025059533A1 (en) | 2023-09-13 | 2025-03-20 | The Broad Institute, Inc. | Crispr enzymes and systems |
| WO2025097055A2 (en) | 2023-11-02 | 2025-05-08 | The Broad Institute, Inc. | Compositions and methods of use of t cells in immunotherapy |
| WO2025117544A1 (en) | 2023-11-29 | 2025-06-05 | The Broad Institute, Inc. | Engineered omega guide molecule and iscb compositions, systems, and methods of use thereof |
Family Cites Families (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3785186T2 (de) | 1986-09-02 | 1993-07-15 | Enzon Lab Inc | Bindungsmolekuele mit einzelpolypeptidkette. |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| US5728388A (en) | 1989-10-03 | 1998-03-17 | Terman; David S. | Method of cancer treatment |
| US6319494B1 (en) | 1990-12-14 | 2001-11-20 | Cell Genesys, Inc. | Chimeric chains for receptor-associated signal transduction pathways |
| IL104570A0 (en) | 1992-03-18 | 1993-05-13 | Yeda Res & Dev | Chimeric genes and cells transformed therewith |
| US5834266A (en) | 1993-02-12 | 1998-11-10 | President & Fellows Of Harvard College | Regulated apoptosis |
| US5869337A (en) | 1993-02-12 | 1999-02-09 | President And Fellows Of Harvard College | Regulated transcription of targeted genes and other biological events |
| US5830462A (en) | 1993-02-12 | 1998-11-03 | President & Fellows Of Harvard College | Regulated transcription of targeted genes and other biological events |
| US20030036654A1 (en) | 1994-08-18 | 2003-02-20 | Holt Dennis A. | Synthetic multimerizing agents |
| US5827642A (en) | 1994-08-31 | 1998-10-27 | Fred Hutchinson Cancer Research Center | Rapid expansion method ("REM") for in vitro propagation of T lymphocytes |
| JP3262724B2 (ja) | 1996-12-25 | 2002-03-04 | 福岡丸本株式会社 | 栽培装置 |
| US6892139B2 (en) * | 1999-01-29 | 2005-05-10 | The Regents Of The University Of California | Determining the functions and interactions of proteins by comparative analysis |
| US6406699B1 (en) | 1999-10-05 | 2002-06-18 | Gary W. Wood | Composition and method of cancer antigen immunotherapy |
| US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| HK1047770A1 (zh) | 2000-02-24 | 2003-03-07 | Xcyte Therapies, Inc. | 细胞的同时刺激与浓缩 |
| JP2005538706A (ja) | 2001-07-12 | 2005-12-22 | ジェファーソン フーテ， | スーパーヒト化抗体 |
| US20040014194A1 (en) | 2002-03-27 | 2004-01-22 | Schering Corporation | Beta-secretase crystals and methods for preparing and using the same |
| US7446190B2 (en) | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
| US7393531B2 (en) * | 2003-01-21 | 2008-07-01 | Arius Research Inc. | Cytotoxicity mediation of cells evidencing surface expression of MCSP |
| EP1636265A2 (en) | 2003-06-25 | 2006-03-22 | Crucell Holland B.V. | Binding molecules for the treatment of myeloid cell malignancies |
| US20130266551A1 (en) | 2003-11-05 | 2013-10-10 | St. Jude Children's Research Hospital, Inc. | Chimeric receptors with 4-1bb stimulatory signaling domain |
| US20100196336A1 (en) | 2006-05-23 | 2010-08-05 | Dongsu Park | Modified dendritic cells having enhanced survival and immunogenicity and related compositions and methods |
| GB0700058D0 (en) | 2007-01-03 | 2007-02-07 | Scancell Aps | Anti-tumor vaccine based on normal cells |
| US8536310B2 (en) | 2007-10-17 | 2013-09-17 | Arca Biopharma, Inc. | Antibodies to CLL-1 |
| JP6069755B2 (ja) * | 2008-11-24 | 2017-02-01 | ヘルムホルツ・ツェントルム・ミュンヘン・ドイチェス・フォーシュンクスツェントルム・フュア・ゲズントハイト・ウント・ウンベルト・ゲーエムベーハー | 高親和性ｔ細胞受容体およびその用途 |
| NZ594985A (en) | 2009-03-10 | 2013-07-26 | Biogen Idec Inc | Anti-bcma (b-cell maturation antigen, cd269, tnfrsf17) antibodies |
| AU2010301042B2 (en) | 2009-10-01 | 2014-03-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer |
| US20120227134A1 (en) * | 2009-11-17 | 2012-09-06 | Basf Plant Science Company Gmbh | Plants with Increased Yield |
| EP2566886A1 (en) | 2010-05-05 | 2013-03-13 | Addex Pharma SA | Methods and tools for screening agents exhibiting an activity on receptors of the tumor necrosis factor receptor superfamily |
| WO2011146862A1 (en) | 2010-05-21 | 2011-11-24 | Bellicum Pharmaceuticals, Inc. | Methods for inducing selective apoptosis |
| ES2754394T3 (es) | 2010-09-08 | 2020-04-17 | Chemotherapeutisches Forschungsinstitut Georg Speyer Haus | Receptores de antígenos quiméricos con una región bisagra optimizada |
| US9493740B2 (en) | 2010-09-08 | 2016-11-15 | Baylor College Of Medicine | Immunotherapy of cancer using genetically engineered GD2-specific T cells |
| US9845362B2 (en) | 2010-10-08 | 2017-12-19 | The University Of North Carolina At Charlotte | Compositions comprising chimeric antigen receptors, T cells comprising the same, and methods of using the same |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| CA3179835A1 (en) | 2011-01-18 | 2012-07-26 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treating cancer |
| WO2012103279A2 (en) | 2011-01-26 | 2012-08-02 | Ariad Pharmaceuticals, Incorporated | Methods and compositions for the synthesis of multimerizing agents |
| NZ743310A (en) | 2011-03-23 | 2022-11-25 | Fred Hutchinson Cancer Center | Method and compositions for cellular immunotherapy |
| PE20141045A1 (es) | 2011-05-27 | 2014-09-10 | Glaxo Group Ltd | Proteinas de union a bcma (cd269/tnfrsf17) |
| EP2532740A1 (en) | 2011-06-11 | 2012-12-12 | Michael Schmück | Antigen-specific CD4+ and CD8+ central-memory T cell preparations for adoptive T cell therapy |
| EA201490636A1 (ru) | 2011-09-16 | 2014-08-29 | Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания | Сконструированные с помощью рнк t-клетки для лечения злокачественных новообразований |
| TWI679212B (zh) | 2011-11-15 | 2019-12-11 | 美商安進股份有限公司 | 針對ｂｃｍａ之e3以及ｃｄ３的結合分子 |
| DE102012204596A1 (de) | 2012-03-22 | 2013-09-26 | Ford Global Technologies, Llc | Verfahren und Vorrichtung zum Regeln der Geschwindigkeit eines Kraftfahrzeugs |
| CA2868121C (en) | 2012-03-23 | 2021-06-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-mesothelin chimeric antigen receptors |
| HK1206601A1 (en) | 2012-04-02 | 2016-01-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of biologics and proteins associated with human disease |
| KR102086874B1 (ko) | 2012-04-11 | 2020-03-10 | 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 | B-세포 성숙 항원을 표적화하는 키메라 항원 수용체 |
| US9163090B2 (en) | 2012-05-07 | 2015-10-20 | Cellerant Therapeutics, Inc. | Antibodies specific for CLL-1 |
| CN110511278B (zh) | 2012-05-07 | 2024-08-09 | 达特茅斯大学理事会 | 抗b7-h6抗体、融合蛋白及其使用方法 |
| WO2014055771A1 (en) | 2012-10-05 | 2014-04-10 | The Trustees Of The University Of Pennsylvania | Human alpha-folate receptor chimeric antigen receptor |
| US10117896B2 (en) | 2012-10-05 | 2018-11-06 | The Trustees Of The University Of Pennsylvania | Use of a trans-signaling approach in chimeric antigen receptors |
| TW201425336A (zh) * | 2012-12-07 | 2014-07-01 | Amgen Inc | Ｂｃｍａ抗原結合蛋白質 |
| US10077315B2 (en) | 2013-02-05 | 2018-09-18 | Engmab Sàrl | Bispecific antibodies against CD3 and BCMA |
| EP2953475B1 (en) * | 2013-02-06 | 2019-07-03 | Celgene Corporation | Modified t lymphocytes having improved specificity |
| KR102064230B1 (ko) | 2013-02-15 | 2020-01-13 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 키메라 항원 수용체 및 이의 이용 방법 |
| KR20150131218A (ko) | 2013-03-14 | 2015-11-24 | 벨리쿰 파마슈티컬스, 인크. | T 세포 증식의 제어 방법 |
| EP3783098A1 (en) | 2013-05-14 | 2021-02-24 | Board Of Regents, The University Of Texas System | Human application of engineered chimeric antigen receptor (car) t-cells |
| CA2956667A1 (en) | 2013-07-29 | 2015-02-05 | Bluebird Bio, Inc. | Multipartite signaling proteins and uses thereof |
| AU2014352638B2 (en) | 2013-11-25 | 2018-08-02 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric antigen receptors to control HIV infection |
| EP3074025A1 (en) | 2013-11-27 | 2016-10-05 | Baylor College Of Medicine | Csgp4-specific chimeric antigen receptor for cancer |
| JP6793902B2 (ja) | 2013-12-20 | 2020-12-02 | ノバルティス アーゲー | 調節可能キメラ抗原受容体 |
| EP4215603A1 (en) | 2014-02-04 | 2023-07-26 | Kite Pharma, Inc. | Methods for producing autologous t cells useful to treat b cell malignancies and other cancers and compositions thereof |
| CN106132423B (zh) | 2014-02-14 | 2020-07-31 | 贝里坤制药股份有限公司 | 用诱导型嵌合多肽活化t细胞的方法 |
| ES2939760T3 (es) | 2014-03-15 | 2023-04-26 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico para antígenos |
| AU2015248956B2 (en) | 2014-04-14 | 2020-06-25 | Cellectis | BCMA (CD269) specific chimeric antigen receptors for cancer immunotherapy |
| JP7054622B2 (ja) * | 2014-07-21 | 2022-04-14 | ノバルティス アーゲー | ヒト化抗ｂｃｍａキメラ抗原受容体を使用した癌の処置 |
| BR112017000939A2 (pt) | 2014-07-21 | 2017-11-14 | Novartis Ag | tratamento de câncer usando um receptor antigênico quimérico de cll-1 |
| SG10201900455YA (en) | 2014-07-24 | 2019-02-27 | Bluebird Bio Inc | Bcma chimeric antigen receptors |
| US9751946B2 (en) | 2014-09-12 | 2017-09-05 | Genentech, Inc. | Anti-CLL-1 antibodies and immunoconjugates |
| AU2015317370A1 (en) | 2014-09-19 | 2017-03-23 | Regeneron Pharmaceuticals, Inc. | Chimeric antigen receptors |
| IL292650B2 (en) * | 2014-09-19 | 2024-04-01 | Hope City | COSTIMULATORY CHIMERIC ANTIGEN RECEPTOR T CELLS TARGETING IL13Ra2 |
| KR20240130831A (ko) | 2014-12-05 | 2024-08-29 | 메모리얼 슬로안 케터링 캔서 센터 | B-세포 성숙화 항원을 표적화하는 키메라 항원 수용체 및 그의 용도 |
| RU2727451C2 (ru) | 2014-12-05 | 2020-07-21 | Сити Оф Хоуп | Т-клетки, модифицированные химерным рецептором антигена, нацеленным на cs1 |
| WO2016094304A2 (en) | 2014-12-12 | 2016-06-16 | Bluebird Bio, Inc. | Bcma chimeric antigen receptors |
| CN105445991A (zh) | 2014-12-26 | 2016-03-30 | 深圳市华星光电技术有限公司 | 彩色滤光片的制作方法 |
| RU2706582C2 (ru) | 2015-04-13 | 2019-11-19 | Пфайзер Инк. | Химерные антигенные рецепторы, нацеленные на антиген созревания B-клеток |
| AU2016248946C1 (en) | 2015-04-13 | 2024-10-17 | Pfizer Inc. | Therapeutic antibodies and their uses |
| CN105384825B (zh) | 2015-08-11 | 2018-06-01 | 南京传奇生物科技有限公司 | 一种基于单域抗体的双特异性嵌合抗原受体及其应用 |
| PT3436030T (pt) | 2016-04-01 | 2022-11-18 | Amgen Inc | Recetores quiméricos e métodos para a sua utilização |
| PL3436079T3 (pl) * | 2016-04-01 | 2021-12-20 | Kite Pharma, Inc. | Antygen chimeryczny i receptory komórek t oraz sposoby ich stosowania |
| SG11201808622SA (en) | 2016-04-01 | 2018-10-30 | Amgen Inc | Chimeric receptors to flt3 and methods of use thereof |
| SG11201808403SA (en) | 2016-04-01 | 2018-10-30 | Kite Pharma Inc | Bcma binding molecules and methods of use thereof |
-
2017
- 2017-03-31 SG SG11201808403SA patent/SG11201808403SA/en unknown
- 2017-03-31 CU CU2018000120A patent/CU20180120A7/es unknown
- 2017-03-31 JP JP2018550679A patent/JP7366543B2/ja active Active
- 2017-03-31 EP EP17776833.0A patent/EP3436036A4/en not_active Withdrawn
- 2017-03-31 TW TW110147901A patent/TWI795133B/zh active
- 2017-03-31 TW TW106111226A patent/TWI707950B/zh active
- 2017-03-31 AU AU2017240150A patent/AU2017240150C1/en active Active
- 2017-03-31 CN CN201780030900.2A patent/CN109414455B/zh active Active
- 2017-03-31 SG SG10201912515XA patent/SG10201912515XA/en unknown
- 2017-03-31 CN CN202310115780.3A patent/CN117903307A/zh active Pending
- 2017-03-31 WO PCT/US2017/025516 patent/WO2017173349A1/en not_active Ceased
- 2017-03-31 AR ARP170100822A patent/AR108067A1/es not_active Application Discontinuation
- 2017-03-31 PE PE2018001932A patent/PE20190120A1/es not_active Application Discontinuation
- 2017-03-31 EA EA201891966A patent/EA201891966A1/ru unknown
- 2017-03-31 KR KR1020187031269A patent/KR102397674B1/ko active Active
- 2017-03-31 TW TW109115604A patent/TWI761831B/zh active
- 2017-03-31 KR KR1020237012515A patent/KR102591930B1/ko active Active
- 2017-03-31 CA CA3019135A patent/CA3019135A1/en active Pending
- 2017-03-31 TW TW112105413A patent/TW202323273A/zh unknown
- 2017-03-31 KR KR1020227015639A patent/KR102522622B1/ko active Active
- 2017-03-31 NZ NZ746700A patent/NZ746700A/en unknown
- 2017-03-31 BR BR112018070159-9A patent/BR112018070159A2/pt not_active IP Right Cessation
- 2017-03-31 CR CR20180462A patent/CR20180462A/es unknown
- 2017-03-31 US US15/476,309 patent/US10689450B2/en active Active
- 2017-03-31 CN CN202310108490.6A patent/CN116425876A/zh active Pending
-
2018
- 2018-09-26 IL IL261942A patent/IL261942A/en unknown
- 2018-09-27 CL CL2018002763A patent/CL2018002763A1/es unknown
- 2018-09-27 PH PH12018550164A patent/PH12018550164A1/en unknown
- 2018-09-28 MX MX2023007400A patent/MX2023007400A/es unknown
- 2018-09-28 CO CONC2018/0010475A patent/CO2018010475A2/es unknown
- 2018-10-01 EC ECSENADI201873836A patent/ECSP18073836A/es unknown
- 2018-10-01 DO DO2018000212A patent/DOP2018000212A/es unknown
- 2018-10-18 ZA ZA2018/06962A patent/ZA201806962B/en unknown
-
2019
- 2019-09-12 US US16/569,341 patent/US11505613B2/en active Active
-
2022
- 2022-02-10 JP JP2022019896A patent/JP2022065073A/ja active Pending
- 2022-02-23 AU AU2022201243A patent/AU2022201243A1/en not_active Abandoned
- 2022-11-14 US US18/055,188 patent/US20230146195A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019515661A5 (enExample) | ||
| JP2019516352A5 (enExample) | ||
| KR102879284B1 (ko) | 항-메소텔린 키메라 항원 수용체(car) 작제물 및 이의 용도 | |
| HRP20221348T1 (hr) | Kimerni receptori i postupci njihove uporabe | |
| JP2019516350A5 (enExample) | ||
| RU2017105065A (ru) | Лечение злокачественного новообразования с использованием гуманизированного химерного антигенного рецептора против всма | |
| AU2015315199B2 (en) | Chimeric receptors and uses thereof in immune therapy | |
| JP2017522879A5 (enExample) | ||
| JP2020513839A5 (enExample) | ||
| JP2017524367A5 (enExample) | ||
| JP2017527271A5 (enExample) | ||
| EP3875484A1 (en) | Cll1-targeting antibody and application thereof | |
| RU2017105160A (ru) | Лечение рака с помощью химерного антигенного рецептора к cd33 | |
| CA3032054A1 (en) | Combination therapies of chimeric antigen receptors and pd-1 inhibitors | |
| JP2018538339A5 (enExample) | ||
| US20150139943A1 (en) | Chimeric receptors and uses thereof in immune therapy | |
| RU2017105161A (ru) | Лечение рака с использованием химерного антигенного рецептора cll-1 | |
| JP2019523301A5 (enExample) | ||
| CN116829194A (zh) | 用于工程化细胞疗法的靶向细胞因子构建体 | |
| JP2017522880A5 (enExample) | ||
| JP2017530694A5 (enExample) | ||
| RU2017108903A (ru) | Химерный антигенный рецептор (car) против cd123 для использования в лечении злокачественных опухолей | |
| US20210128618A1 (en) | Bcma-targeted car-t cell therapy of multiple myeloma | |
| JPWO2016028896A5 (enExample) | ||
| JPWO2020180591A5 (enExample) |